Futura Medical head of R&D details progress on WSD4000 for women

Proactive - Interviews for investors

Futura Medical PLC (AIM:FUM, OTC:FAMDF) head of R&D Ken James talked with Proactive's Stephen Gunnion about the company’s groundbreaking advancements in sexual health. Futura, a UK-based innovator, specialises in the development of patented sexual health products. Its lead product, Eroxon, a topical gel for male erectile dysfunction, has been launched globally, including in the United States. James introduced the company's latest product, WSD4000, a topical gel for women designed to address common symptoms of sexual dysfunction like low arousal, poor lubrication, and reduced orgasmic function. Targeted for over-the-counter use, WSD4000 aims to fill a gap in the market as no regulatory-approved options currently exist. He shared promising results from a Home User Study involving 67 volunteers, showing significant improvements in lubrication, arousal, and overall sexual satisfaction. The study also demonstrated strong user engagement, with 57% exceeding the required usage. Looking ahead, James outlined plans for regulatory approval, starting with a feasibility study in 2025. The company intends to conduct a pivotal clinical study following discussions with the FDA, aiming for substantial market impact. Visit Proactive’s YouTube channel for more interviews like this one. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future updates! #FuturaMedical #WSD4000 #Eroxon #SexualHealth #WomenWellness #ClinicalResearch #FDAApproval #HealthcareInnovation #TopicalGels